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Milk enriched in conjugated linoleic acid (CLA) was obtained from cows on pasture supplemented with full-fat rapeseeds (FFR; 2·26 g
cis 9, trans 11 (c9, t11)-CLA/100 g fatty acid methyl esters) and full-fat soyabeans (1·83 g c9, t11-CLA/100 g fatty acid methyl esters).
A control milk fat (1·69 g c9, t11-CLA/100 g fatty acid methyl esters) was obtained from cows fed on pasture only. The present
study assessed the potency of the CLA-enriched milk fats to modulate biomarkers that had previously been observed to respond to c9,
t11-CLA in the MCF-7 and SW480 cell lines. Cell numbers decreased (P,0·05) by up to 61 and 58 % following the incubation of
MCF-7 and SW480 cells, respectively, for 4 d with milk fats (yielding CLA concentrations between 60·2 and 80·6mM). The FFR milk
fat, containing the highest CLA content, increased (P,0·05) [14C]arachidonic acid (AA) uptake into the monoacylglycerol fraction of
MCF-7 and SW480 cells while it decreased (P,0·05) uptake into the phospholipid fraction of the latter. This milk fat also decreased
(P,0·05) [14C]AA conversion to prostaglandin (PG) E2 while increasing conversion to PGF2a in both cell lines. All milk-fat samples
increased (P,0·05) lipid peroxidation as measured by 8-epi-PGF2a in both cell lines. In SW480 cells the milk-fat samples decreased
(P,0·05) bcl-2 and cytosolic glutathione levels while increasing (P,0·05) membrane-associated annexin V levels. All milk-fat samples
decreased (P,0·05) the expression of ras in SW480 cells. These data suggest that milk-fat CLA was effective at modulating synthetic
CLA-responsive biomarkers.
Milk fat: Conjugated linoleic acid: Eicosanoids: Apoptosis
A growing number of dietary components with putative
health-promoting properties are being identified and a new
class of foods, so-called functional foods, has emerged
(Milner, 1999). Research is unveiling milk fat as a source
of bioactive components including minerals, peptides
derived from milk proteins and lipid components (Boland
et al. 2001; Calder, 2002). Of particular interest is the
fatty acid conjugated linoleic acid (CLA), which has con-
sistently been shown to inhibit chemically induced tumour
development in animal models at a number of sites includ-
ing skin (Belury et al. 1996), mammary gland (Ip et al.
1994), forestomach (Ha et al. 1990) and colon (Liew et al.
1995). In addition, cell culture studies have shown CLA to
inhibit the growth of human cancer cell lines including those
of the colon (Miller et al. 2001; Palombo et al. 2002), breast
(Park et al. 2000; Miller et al. 2001) and prostate (Palombo
et al. 2002) at micromolar concentrations. CLA is produced
in ruminant animals and as a result milk fat is among the
richest natural sources of CLA, with the cis 9, trans 11
(c9, t11)-CLA isomer being the predominant form, account-
ing for up to 90 % of total milk-fat CLA (Chin et al. 1992).
While CLA is formed in ruminant animals as a first inter-
mediate in the microbial biohydrogenation of linoleic acid
(LA) by the action of a bacterial LA isomerase (Kepler &
Tove, 1967), endogenous synthesis from trans-vaccenic
acid (TVA) represents a more significant source of c9,
t11-CLA in milk fat (Griinari et al. 2000).
Because of the health-promoting properties associated
with CLA, attempts have been made to enrich its content
in milk fat. Animal diet has a major impact on the CLA
content of milk fat and several studies have shown that it
can be elevated by modifying the dietary regimen of the
dairy cow (Lawless et al. 1998; Chilliard et al. 2000),
thus offering the possibility of producing CLA-enriched
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dairy products. Ip et al. (1999) have reported that feeding
CLA-enriched butterfat (41 mg/g fat) alters mammary
gland morphogenesis and reduces mammary cancer risk
in rats by the same magnitude as a synthetic mixture of
CLA isomers and a synthetic c9, t11-CLA preparation.
The group consuming the butterfat consistently accumulated
more total CLA in their tissues compared with the group
consuming the synthetic CLA preparations and the authors
suggested that TVA in the butterfat may have been a precur-
sor for the endogenous synthesis of CLA. In a more recent
study, this CLA-enriched butterfat effectively suppressed
the proliferative activity and the expression of cell cycle
regulating proteins (cyclin D1 and A) in the developing rat
mammary epithelium (Ip et al. 2001).
It has previously been reported that the mammary MCF-7
and colon SW480 cancer cell lines were sensitive to the
cytotoxic effect of a CLA mixture of isomers and the c9,
t11-CLA isomer (Miller et al. 2001). The CLA-induced
cytotoxicity was related to an increase in lipid peroxidation
(O’Shea et al. 1999; Miller et al. 2001). The cytotoxicity
was also related to alterations in the mobilisation and metab-
olism of arachidonic acid (AA) (Miller et al. 2001), a
reduction in the level of the anti-apoptotic bcl-2 protein,
which triggered a cascade of events leading to apoptosis
(Miller et al. 2002) and the modulation of ras expression
(McGrath et al. 2001). CLA-enriched milk fat was pre-
viously reported to be taken up by MCF-7 cells and to be
more effective than synthetic CLA at decreasing MCF-7
cell numbers and increasing lipid peroxidation after an 8 d
incubation period (O’Shea et al. 2000). These effects were
independent of the variable composition of the milk-fat
samples, suggesting that CLA may be the active ingredient
responsible for the cytotoxic effect in MCF-7 cells. The pre-
sent study investigated whether fatty acids (LA, TVA and
oleic acid) present in CLA-enriched milk fats could influ-
ence the growth of MCF-7 and SW480 cells. The potency
of CLA-enriched milk fats to modulate CLA-responsive
biochemical and molecular biomarkers previously observed
in the MCF-7 and SW480 cell lines (Miller et al. 2001,
2002) was assessed. Specifically, the effects of CLA-
enriched milk fats on: (1) AA uptake, distribution and con-
version to eicosanoid classes in MCF-7 and SW480 cell
lines; (2) lipid peroxidation; (3) apoptotic markers in the
SW480 cells line (reduced glutathione (GSH) levels, mem-
brane annexin V levels and bcl-2 expression); (4) levels of
ras expression in SW480 cells were assessed.
Materials and methods
Cell culture conditions
Human breast (MCF-7) and colon (SW480) cancer cell
lines were obtained from the American Type Culture Col-
lection (Manassas, VA, USA). Culture media and sup-
plements were purchased from Sigma-Aldrich Ireland
Ltd. (Dublin, Republic of Ireland). The SW480 cells
were maintained in Dulbecco’s minimum essential
medium supplemented with fetal bovine serum (5 %,
v/v), 0·2 mM-L-glutamine, 1 mM-N0-(2-hydroxyethyl)piper-
azine-N-2-ethanesulfonic acid, and 1 unit each of
penicillin and streptomycin/ml. The MCF-7 cells required
an additional supplement of 10 mM-sodium pyruvate.
Cells were grown in Falcon T-75 cm2 flasks and main-
tained as previously described (O’Shea et al. 1999).
Milk-fat samples
The milk fats used in the present study were obtained fol-
lowing the supplementation of lactating dairy cows on pas-
ture (control) or on pasture supplemented with full-fat
rapeseeds (FFR) or full-fat soyabeans (FFS) for 33 and
34 d, respectively (Lawless et al. 1998). Table 1 summar-
ises the concentrations of CLA, oleic acid, TVA and LA
in the milk-fat samples. The full fatty acid composition
was as described by O’Shea et al. (2000).
Quantification of cell numbers
Cells were seeded in six-well plates and the MCF-7 and
SW480 cells were seeded at densities of 1 £ 105/well and
5 £ 104/well respectively. Cells were cultured for 24 h to
allow the cells to attach to the substratum. The medium
was then replaced with media containing either FFR milk
fat, FFS milk fat or control milk fat at a concentration of
1 mg/ml to yield CLA concentrations of 60·2, 65·2 and
80·6mM, respectively. Control wells were supplemented
with equivalent volumes of ethanol (0·1 % final concen-
tration, v/v). In a separate experiment, the milk-fat content
of the medium was varied between 0·8 and 1·2 mg/ml to
yield a CLA concentration of 71·3mM in all milk-fat
samples. Cells were also incubated in the presence of c9,
t11-CLA (95 % pure; Natural ASA, Hovdebygda,
Norway), LA, TVA or oleic acid (all 99 %; Sigma-Aldrich
Ireland Ltd.) at concentrations similar to those found in the
milk-fat samples. For all viability experiments, the cells
were harvested in the presence of PBS containing 0·25 %
(v/v) trypsin. Viable cell numbers were quantified using
the trypan blue exclusion (0·4 %, w/v) assay.
Uptake of [14C]arachidonic acid and conversion to
eicosanoids
Cells were seeded in T-25 cm2 flasks at a density of 2 £ 105/
flask and grown to 90 % confluency. The medium was then
replaced with a medium containing [14C]AA at 0·2mCi
along with the milk-fat samples control, FFS or FFR (all
added at a milk-fat concentration of 1 mg/ml yielding
CLA concentrations of 60·2, 65·2 and 80·6mM, respectively)
or an equivalent volume of ethanol. After 24 h incubation,
the cells were harvested to determine the uptake of
Table 1. Fatty acid composition of milk-fat samples (g/100 g fatty
acid methyl esters)
Fatty acid
Control
milk fat
FFS
milk fat
FFR
milk fat
CLA 1·69 1·83 2·26
Trans-vaccenic acid 3·14 4·41 4·64
Oleic acid 20·28 23·37 26·92
Linoleic acid 1·25 4·28 1·69
FFS, full-fat soyabean; FFR, full-fat rapeseed; CLA, conjugated linoleic acid.
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[14C]AA and the media were collected. Total cellular lipids
were extracted from the cell pellet and then separated into
triacylglycerol, monoacylglycerol (MG) and phospholipid
fractions as described by Miller et al. (2001). A sample of
each fraction was counted in a Beckman LS6500 scintil-
lation counter (Beckman Instruments, Galway, Republic
of Ireland). Eicosanoids were extracted as described by
Miller et al. (2001). Eicosanoid extracts were dried under
N2, re-dissolved in ethyl acetate separated using normal-
phase TLC as described previously (Miller et al. 2001).
Bands of prostaglandin (PG) E2, PGF2a, and PGD2 were
removed from the TLC plates and placed in vials for count-
ing by liquid scintillation. The isoprostane 8-epi-PGF2a was
extracted from the media as described by Watkins et al.
(1999) and a competitive horseradish peroxidase enzyme-
linked immunoassay kit (BIOXYTECH 8-Isoprostane
assay system; Bio-Stat Ltd, Stockport, Cheshire, UK) was
used to quantify 8-epi-PGF2a levels according to the man-
ufacturer’s instructions. 5-Hydroperoxyeicosatetraenoate
was measured using a colorimetric method developed by
Waslidge & Hayes (1995).
Measurement of reduced glutathione and annexin V levels
Cells were seeded in T-75 cm2 flasks at a density of
1 £ 106 cells/flask and incubated for 24 h. The medium
was then replaced with fresh media containing the milk-
fat samples; control, FFS or FFR (1 mg/ml) as described
earlier and incubated for 4 d, after which both floating
and adherent cells were collected and pooled. Cells were
then re-suspended in a PBS–phenylmethylsulfonylfluoride
buffer (10 mM-sodium phosphate buffer (pH 7·2), 100 mM-
NaCl, 0·2 mM-phenylmethylsulfonylfluoride) containing
0·1 mM-leupeptin and 0·2mg aprotinin/ml (both from
Sigma-Aldrich Ireland Ltd.) as protease inhibitors, soni-
cated on ice and centrifuged at 100 000 g for 1 h at 48C.
The supernatant fraction (cytosolic fraction) was analysed
for GSH levels according to the method of Hissin & Hilf
(1976). The pellet was re-suspended in a lysis buffer
(10 mM-sodium phosphate buffer (pH 7·2), 0·2 mM-phenyl-
methylsulfonylfluoride and 100 mM-NaCl) containing
0·1 mM-leupeptin and 0·2mg aprotinin/ml and incubated
on ice for 20 min followed by centrifugation at 15 000 g
for 15 min at 48C. The resulting supernatant fraction (mem-
brane fraction) was analysed for annexin V content using
an Annexin V ELISA kit (Alexis Biochemicals, San
Diego, CA, USA) according to the manufacturer’s instruc-
tions. The GSH and annexin V concentrations of the
samples were determined from standard curves and
expressed relative to the protein content, as determined
using the Bio-Rad protein assay (Biorad, Hemel Hemp-
stead, Herts, UK).
Measurement of bcl-2 and ras expression
SW480 cells were seeded at 5 £ 106 cells/150 cm2 flask and
were cultured for 24 h to allow the cells to attach to the sub-
stratum. The medium was then replaced with fresh media
containing the milk-fat samples; control, FFS or FFR
(1 mg/ml). After 4 d of incubation, both floating cells and
adherent cells were collected and pooled. Cells were
washed twice in ice-cold PBS and re-suspended in the lysis
buffer (described earlier). Lysates were sonicated using a
Vibra Cell VC502 (Sonics, Newtown, CT, USA) on ice
and concentrated using Microconsw (Millipore, Cork,
Republic of Ireland). Protein concentrations were deter-
mined using the Bio-Rad protein assay (Biorad). SDS-
PAGE and Western blots were performed essentially by
the methods of Laemmli (1970) and Towbin et al. (1979),
respectively. Lysates containing approximately 70mg pro-
tein were solubilised in a sample buffer (10 % (w/v) SDS,
600 mM-tri(hydroxymethyl)-aminomethane-HCl (pH 6·7),
and 50 % (w/v) glycerol) containing b-mercaptoethanol
and 50mg bromophenol blue/ml. Samples were boiled for
2 min and proteins resolved by electrophoresis and blotted
onto Hybond enhanced chemiluminescence membrane
(Amersham, Little Chalfont, Buckinghamshire, UK) in a
Trans-blot Electrophoretic transfer cell (Biorad). Blots
were stained with Ponceau S solution (0·2 %, w/v) to
ensure the transfer of proteins was complete and to determine
if equivalent amounts of protein were loaded in each lane.
The blots were destained with PBS containing 0·1 % (v/v)
Tween 20 (PBST) and blocked with 5 % (w/v) non-fat dry
milk dissolved in PBST. Blots were then incubated with
monoclonal antibodies: anti-bcl-2 diluted to 1:1000
(Sigma-Aldrich Ireland Ltd.) or anti-ras diluted to 1:40
(Oncogene Science, Manhasset, NY, USA) in PBST contain-
ing 0·5 % (w/v) non-fat dry milk. Blots were washed exten-
sively in PBST and re-incubated with a horseradish
peroxidase-linked secondary antibody (Amersham) diluted
1:2000 in PBST containing 0·5 % (w/v) non-fat dry milk.
The blots were then thoroughly washed in excess PBST
and probed with the Super Signal detection system (Pierce,
Rockford, IL, USA) and exposed to autoradiography films
(Amersham) according to the manufacturer’s instructions.
Densitometry (using NIH Image software; Research
Services Branch, Bethesda, MD, USA) was performed on
Ponceau S scans and autoradiographs.
Statistical analysis
Three independent experiments were performed in tripli-
cate. One-way ANOVA, followed by post hoc testing by
Tukey’s honestly significant difference test, was used to
analyse the data. For treatments with more than one
factor, factorial ANOVA followed by post hoc testing by
Tukey’s honestly significant difference test was carried out.
Results
The effects of conjugated linoleic acid-enriched milk fat on
cell viability
MCF-7 and SW480 cells were incubated for 4 d in the pre-
sence of milk fat (1 mg/ml) to yield CLA concentrations in
the range from 60·2 to 80·6mM. This allowed the examin-
ation of the effect of increasing milk-fat CLA concentration
while the milk fat content was kept constant. A previous
study had shown that there was a proportional increase
in CLA uptake from these milk fats by MCF-7 cells (O’Shea
et al. 2000), suggesting a cellular lipolytic competence
for milk-fat triacylglycerols. Cell numbers following 4 d
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of incubation with all three milk fats were significantly
(P,0·05) lower than the number of untreated control
cells (Figs. 1 (A) and 1 (B)). A dose-dependent decrease
in cell number was observed with increasing CLA content
in the milk fats, with both FFS and FFR being significantly
(P,0·05) more potent than the control milk fat. Maximal
growth inhibition of 61 and 58 % occurred in the MCF-7
and SW480 cells, respectively, following treatment with
the highest milk-fat CLA concentration. A significant
(P,0·05) inhibitory effect on cell number was obtained
following the incubation of both cell lines with c9, t11-
CLA at 60·2, 65·2 and 80·6mM, representing the concen-
trations present in the control, FFS and FFR milk fats,
respectively (Figs. 1 (A) and 1 (B)). The respective percen-
tages by which cell viability was reduced following the
addition of c9, t11-CLA to the medium were 43, 46 and
49 in the MCF-7 cell line and 41, 44 and 50 in the
SW480 cell line. In the MCF-7 cell line, milk fat CLA
(60·2 and 65·2mM) was significantly (P,0·05) more effec-
tive at decreasing cell numbers when compared with the
synthetic c9, t11-CLA at the same concentrations. In the
SW480 cell line no significant difference was observed
between the milk-fat CLA and synthetic c9, t11-CLA treat-
ments suggesting that lipase activities may differ between
cell lines and may possibly be rate limiting in the MCF-7
cell line.
The milk-fat content of the medium was then varied
between 0·8 and 1·2 mg/ml to yield a final CLA milk-fat
concentration of 71·3mM. All milk-fat samples signifi-
cantly (P,0·05) lowered cell numbers compared with the
untreated control cells after 4 d incubation by approxi-
mately 58 and 53 % in MCF-7 and SW480 cells respect-
ively (Figs. 2 (A) and 2 (B)). No significant differences
in final cell numbers were obtained for all milk-fat treat-
ments in either cell line.
To elucidate the effects of individual fatty acids present
in the milk fat on cell viability, cells were incubated in the
presence of pure LA, TVA or oleic acid at concentrations
similar to those found in the milk-fat samples and viability
was assessed after 4 d incubation (Figs. 3 (A) and 3 (B)).
TVA significantly decreased (P,0·05) cell viability by
approximately 22–37 % in both cell lines when added at
the concentrations present in the three milk-fat samples
(111·2, 156·1 and 164·2mM in the control, FFS and FFR,
respectively). The MCF-7 cells were more sensitive to
the growth inhibitory effects of TVA. When cells were
incubated in the presence of LA at the concentrations pre-
sent in the three milk-fat samples (44·6, 152·5 and 60·2mM
in the control, FFS and FFR, respectively) differential
effects on growth were observed. In the MCF-7 cell line,
LA at a concentration of 44·6mM significantly (P,0·05)
stimulated cell growth by 26 % but at a concentration of
152·5mM LA was cytotoxic to the cells inhibiting cell
growth by 43 %. LA at 60·2mM had no significant effect
on final cell numbers. In the SW480 cell line, LA at 44·6
and 60·2mM stimulated cell growth but the increase was
only significant at the higher LA concentration. When
LA was added at a concentration of 152·5mM, SW480
cell growth was significantly (P,0·05) inhibited by
40 %. The latter cell line was more sensitive to the
growth-modulatory effects of oleic acid than the MCF-7
cell line. Incubation with oleic acid significantly decreased
cell numbers in the MCF-7 only at the highest con-
centration of 952·9mM, which was representative of the
concentration found in the FFR milk-fat sample. In contrast,
Fig. 1. Growth of (A) MCF-7 and (B) SW480 cells incubated with
milk-fat samples (B) or synthetic cis 9, trans 11-conjugated linoleic
acid (CLA) (A) containing varying levels of CLA for 4 d. a,b,c Mean
values within a concentration with unlike superscript letters were
significantly different (P,0·05) or significantly different from the
control (P,0·05).
Fig. 2. Growth of (A) MCF-7 and (B) SW480 cells incubated with
milk-fat samples containing 20mg conjugated linoleic acid (CLA)/ml
(71·3mM-CLA) for 4 d. CF, control fat; FFS, full-fat soyabean; FFR,
full-fat rapeseed. * Mean values were significantly different to those
for the control cells (P,0·05).
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incubation of SW480 cells with oleic acid at 717·8, 827·3
and 952·9mM, representing the concentrations present in
control, FFS and FFR milk fats respectively, significantly
(P,0·05) decreased cell viability by 13, 26 and 39 %,
respectively.
Effect of conjugated linoleic acid-enriched milk fat on
incorporation of [14C]arachidonic acid into cellular lipid
fractions
In order to examine if growth inhibition by milk fat could
be attributed to an altered pattern of AA distribution and
eicosanoid formation, the effects of the three milk-fat
samples on the incorporation of [14C]AA into the cellular
lipid fractions of MCF-7 and SW480 cells were investi-
gated. The control fat, FFS and FFR milk fats were
added at 1 mg/ml milk fat to yield CLA milk-fat concen-
trations of 60·2, 65·2 and 80·6mM, respectively. Levels of
[14C]AA uptake into phospholipid, triacylglycerol and
MG were 64, 27 and 9 %, respectively, in control MCF-7
cells and 74, 22 and 4 %, respectively, in control SW480
cells (Figs. 4 (A) and 4 (B)). These patterns of AA incor-
poration are similar to those previously reported in these
cell lines (Miller et al. 2001). In both cell lines, only incu-
bation with the FFR milk fat, containing the highest CLA
levels (80·6mM), caused perturbations in [14C]AA uptake
(Figs. 4 (A) and 4 (B)). In the MCF-7 cell line, treatment
with FFR milk fat significantly (P,0·05) increased
[14C]AA uptake into the MG fraction by 10 %. In SW480
cells, FFR milk-fat treatment also resulted in a significant
(P,0·05) increase in [14C]AA uptake into the MG fraction
(by 8 %) and this was accompanied by a significant
(P,0·05) decrease in uptake into the phospholipid fraction
(by 12 %).
Effect of conjugated linoleic acid-enriched milk fat on
eicosanoid and 8-epi-prostaglandin F2a synthesis
The effects of the control, FFS and FFR milk-fat treatments
(all added at 1 mg milk fat/ml) on the enzymic conversion
of AA to selected eicosanoids (PGD2, PGE2, and PGF2a
and 5-hydroperoxyeicosatetraenoate) and on the oxidation
to 8-epi-PGF2a were examined. In both cells lines, only
the FFR milk-fat treatment altered the eicosanoid profile
(Figs. 5 (A) and 5 (B)). Following the incubation of both
cell lines with FFR milk fat, [14C]AA conversion to
Fig. 3. Growth of (A) MCF-7 and (B) SW480 cells incubated with trans-vaccenic acid (TVA), linoleic acid (LA) and oleic acid (OA) at concen-
trations similar to those present in the milk-fat samples. * Mean values were significantly different to those for the control cells (P,0·05).
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PGE2 was significantly (P,0·05) decreased (by approxi-
mately 21–25 %) while the conversion to PGF2a was
significantly (P,0·05) increased (by 23–27 %). A CLA
dose-dependent increase in the isoprostane 8-epi-PGF2a,
a biomarker of lipid peroxidation, was observed in both
cell lines following incubation with the three milk fats.
Maximal stimulation of 8-epi-PGF2a production by 73
and 92 % was observed in MCF-7 and SW480 cells
respectively, following treatment with the FFR milk fat,
which contained the highest CLA concentration. None of
the milk-fat treatments significantly altered the production
of 5-hydroperoxyeicosatetraenoate or PGD2.
Effect of conjugated linoleic acid-enriched milk fat on
apoptotic markers in SW480 cells
To determine if the cytotoxic effect of the milk-fat
samples was executed via an induction of an apoptotic
signalling pathway effects on cytosolic GSH content,
membrane annexin V levels and bcl-2 expression were
examined. The data demonstrate that treatment of
SW480 cells with the milk-fat samples significantly
(P,0·05) reduced bcl-2 protein expression by 23–36 %
(P,0·05) in a milk-fat CLA concentration-dependent
manner (Fig. 6). All milk-fat samples depleted cytosolic
GSH by approximately 21–39 % in SW480 cells, with
Fig. 4. Percentage distribution of [14C]arachidonic acid (AA) radio-
activity into phospholipids (AB), triacylglycerol (A) and monoacylgly-
cerol (B) following 24 h treatment of MCF-7 (A) and SW480 (B)
cells with milk-fat samples (1 mg/ml). FFR, full-fat rapeseed; FFS,
full-fat soyabean; CF, control fat. *Mean values were significantly
different to those for the control cells (P,0·05).
Fig. 5. Percentage distribution of arachidonic acid (AA) into eicosanoids following 24 h treatment of MCF-7 (A) and SW480 (B) cells with milk-
fat samples (1 mg/ml) relative to control untreated cells (100 %). (B), Control fat; (AB), full-fat soyabean; (A), full-fat rapeseed; PG, prostaglan-
din; 5-HPETE, 5-hydroperoxyeicosatetraenoate. * Mean values were significantly different to those for the control cells (P,0·05).
A´. Miller et al.882
both FFS and FFR milk fats exerting a more potent effect
(P,0·05) than control milk fat (Fig. 7). All milk-fat treat-
ments significantly (P,0·05) increased levels of annexin
V (29–32 %) in the cell membrane when compared with
concentrations found in the membrane preparations of
untreated SW480 cells (Fig. 7).
Effect of conjugated linoleic acid-enriched milk fat on ras
expression
The effect of the milk-fat samples on total ras expression in
the SW480 cell line, which overexpresses k ras (Geiser
et al. 1989), was examined. Fig. 8 shows a representative
example of a Western blot analysis of ras in cells treated
with control fat, FFS or FFR milk fat for 4 d. Ras appeared
as a doublet with the upper band representing farnesylated
membrane-bound ras and the lower band representing non-
lipid-modified ras p21. Incubation of SW480 cells with
control, FFS and FFR milk-fat samples (at 1 mg/ml)
decreased the amounts of total ras by 35, 45 and 52 %,
respectively, relative to untreated cells.
Discussion
A prospective cohort study in Finland revealed that
women who developed breast cancer had consumed less
milk than cancer-free women and suggested that CLA
may be the component in milk providing the protective
effect (Knekt et al. 1996). Another study revealed an
inverse association between dietary intake and serum
CLA and the risk of breast cancer in post-menopausal
women (Aro et al. 2000). Individuals with a high con-
sumption of milk had a potentially reduced risk of colon
cancer (Jarvinen et al. 2001). Using food duplicate meth-
odology, the c9, t11-CLA intake in the USA was esti-
mated to be approximately 193 and 140 mg/d for men
and women, respectively (Ritzenthaler et al. 2001). The
authors of the present study suggest that c9, t11-CLA
intake must be increased approximately 3-fold to achieve
consumption levels that can exhibit a cancer-protective
effect (i.e. 0·1 g/100 g diet). A natural approach to enhan-
cing CLA in dairy products is to increase the CLA content
of milk fat by modifying the dietary regimen of the dairy
cow. The FFR milk fat used in the present study con-
tained 1·3-fold higher c9, t11-CLA concentration than
the control fat.
The present study confirmed the cytotoxic effect of milk-
fat CLA in MCF-7 cells previously reported after 8 d incu-
bation (O’Shea et al. 2000) and also showed that the
SW480 cell line is sensitive to the growth-inhibitory
effects of milk-fat CLA. Triacylglycerol-bound milk-fat
CLA was as effective an anticancer agent as the non-ester-
ified fatty acid form of the c9, t11-CLA in the SW480 cells
and even better in the MCF-7 cells, suggesting that lipoly-
sis is an active process in these cells and that lipase activity
may be rate limiting in the MCF-7 cell line.
Evidence is emerging that individual fatty acids, even
within the same fatty acid type (for example, c9, t11-CLA
and LA) may have different effects on carcinogenesis,
tumour growth and metastasis (Zhou & Blackburn, 1999).
The present study evaluated the individual effect of four
Fig. 6. Expression of bcl-2 in SW480 cells following 4 d treatment
with milk-fat samples (1 mg/ml). CF, control fat; FFS, full-fat soya-
bean; FFR, full-fat rapeseed. a,b,c Mean values with unlike super-
script letters were significantly different (P,0·05).
Fig. 7. Levels of cytosolic reduced glutathione (B; nmol/mg protein)
and membrane annexin V (A; ng/mg protein) following 4 d treatment
of SW480 cells with milk-fat samples (1 mg/ml). CF, control fat;
FFS, full-fat soyabean; FFR, full-fat rapeseed. a,b,cMean values
within a variable (glutathione or annexin V) with unlike superscript
letters were significantly different (P,0·05).
Fig. 8. Expression of ras in SW480 cells following 4 d treatment
with milk-fat samples (1 mg/ml). CF, control fat; FFS, full-fat soya-
bean; FFR, full-fat rapeseed. * Mean values were significantly differ-
ent to those for the control cells (P,0·05).
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fatty acids, at concentrations similar to those found in the
three milk-fat samples, on the cell growth of SW480 and
MCF-7 human cancer cell lines. An inhibitory effect on
cell growth was obtained following the incubation of both
cell lines with the pure c9, t11-CLA isomer (at concen-
trations similar to those present in the three milk-fat
samples), confirming the well-established cytotoxic effect
of CLA in these two cell lines. When media were sup-
plemented with synthetic TVA, at concentrations similar
to those present in the three milk-fat samples, cell viability
significantly decreased in both cell lines. It has been shown
that TVA decreases cell growth and evidence has been pro-
vided to suggest that the growth-suppression responses of
both cell lines to TVA are probably mediated by its desa-
turation to c9, t11-CLA (Miller et al. 2003). LA was
either stimulatory or had no effect on cell growth when
incubated with the cells at the lower concentrations found
in the control (44·6mM) and FFR (60·2mM) milk fats. How-
ever, 152·5mM-LA, the concentration present in the FFS
milk fat, had a potent cytotoxic effect and was of similar
magnitude to CLA on the growth of both cell lines. Oleic
acid decreased the viability of SW480 cells when added
at concentrations similar to those present in the three
milk-fat samples but only decreased cell numbers in
MCF-7 cells at the highest concentration of 952·9mM. If
the cytotoxic effects of these fatty acids in milk fat are addi-
tive, it would be expected that the accumulative growth-
suppression effect by milk fats would be much greater
than that observed and would vary as milk-fat content of
the medium varied. The observation that final cell numbers
were similar when the milk-fat content of the medium was
varied to yield a final CLA milk-fat concentration of
71·3mM suggests that the effects of these fatty acids when
in triacylglycerol-bound form in milk fat are lessened.
Yet, when cells were treated with milk fats containing
increasing amounts of CLA they exhibited a dose-depen-
dent decrease in cell number. These data support the earlier
conclusion of Ip et al. (1996) that CLA is a unique fatty acid
with anticancer properties acting independently of other
fatty acids.
It has previously been reported that the growth-suppres-
sive effect of the c9, t11-CLA isomer was associated with
changes in AA distribution among cellular lipids and an
altered PG profile (Miller et al. 2001). In the present
study FFR milk fat increased [14C]AA uptake into the
MG fraction of MCF-7 cells but decreased [14C]AA
uptake into the phospholipid fraction. The FFR milk fat
decreased [14C]AA conversion to PGE2 while increasing
conversion to PGF2a. This altered pattern of eicosanoid
production is similar to that previously observed following
c9, t11-CLA treatment (Miller et al. 2001).
As observed with the pure c9, t11-CLA isomer (Miller
et al. 2001), treatment of the two cell lines with all three
milk fats increased the levels of 8-epi-PGF2a, a biomarker
of lipid peroxidation. Studies suggest that oxidative
stress, in general, and lipid peroxidation in particular are
involved in both the initiation and mediation of apoptosis
(Lopaczynski & Zeisel, 2001). The depletion of GSH
furthers enhances oxidative stress within cells and has
been associated with cytochrome c release (Tang et al.
1998). A balance between beneficial effects (such as
apoptosis) and detrimental effects (for example, oxidative
damage induced by the peroxidative process) may be con-
trolled by factors such as the concentration or structure of
specific antioxidants or by how they distribute intracellu-
larly. The treatment of cells with all milk-fat samples
depleted cytosolic GSH. The milk fat modulated bcl-2 pro-
tein levels, reducing its expression in a CLA concentration-
dependent manner and increased levels of annexin V in cell
membranes in a similar manner to the pure c9, t11-CLA
previously reported (Miller et al. 2002). It can be con-
cluded from these data that the incubation of SW480
cells with milk fats resulted in a cellular condition compa-
tible with the induction of apoptosis. The treatment of
SW480 cells with TVA and c9, t11-CLA was shown to
have decreased total ras expression following 4 d of incu-
bation (Miller et al. 2003). Ras is a central player in mem-
brane-to-nucleus signal transduction and has several
downstream targets, including the mitogen-activated
protein kinase pathway, which is involved in cellular
proliferation (Campbell et al. 1998). Mutations in the
dominant oncogene ras represent the most commonly
found gene mutations in human cancer cells (Gibbs et al.
1994). The present study now shows that CLA-enriched
milk fats may also influence ras signalling by reducing
its expression. Further comparative studies with other
fatty acids are required to validate the use of bcl-2 and/
or ras as specific biomarkers of CLA exposure.
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